IKZF1 and precursor B-cell acute lymphoblastic leukemia: Imatinib, as an intensifying therapy for childhood B-ALL with IKZF1-del, significantly decreased the risk of recurrence and improved the 5-years OS from 69.6% in MS2003 to 91.6% in MS 2010 (p = 0.007) (NCT0289464) (Yeoh et al., 2018).